3. Electronic Theses and Dissertations (ETDs) - All submissions
Permanent URI for this communityhttps://wiredspace.wits.ac.za/handle/10539/45
Browse
6 results
Search Results
Item Molecular basis of metabolic reprogramming in innate immune cells: impact of drugs on the mitochondrial function(2016) Xelwa, Ntombikayise Hendrietta MarciaThis study focused on reprogramming of energy metabolism of cancer cells, since most cancer and proliferating cells have been shown to display a metabolic shift by displaying increased dependence on glycolysis and reduced oxidative phosphorylation (OXPHOS) for energy. Dichloroacetate (DCA) and Methyl pyruvate (MP) were used to attempt the reversal of the metabolic program of THP-1 cells. Flow cytometry was used to determine the mode of cell death and to analyse the changes in cell cycle. In this study, an overexpression of TLR4 was observed in THP-1 cells treated with 5ng/ml of lipopolysaccharides (LPS). Further analysis of cell death showed that MP and DCA-treated cells resulted to minimal induction of apoptotic cell death. This suggests that the 2 drugs (MP and DCA) cause cell death via apoptosis. Furthermore, LPS treated cells (infected cancer cells) showed an increase in glycolysis (Warburg effect). This study has shown that indeed treatment with drugs such as MP and DCA was effective in reversing the glycolytic phenotype of THP-1 cells, resulting in cell death via apoptosis by boosting OXPHOS.Item Targeting retinoblastoma binding protein 6 (RBBP6) as an anti-ovarian cancer therapeutic strategy(2015-05-07) Ubanako, Philemon NjendeOvarian cancer is the most lethal gynaecological cancer. About 90% of ovarian cancers are epithelial (ovarian carcinomas), thought to arise from the ovarian surface epithelium. Diagnosed usually at clinically advanced stages, many patients show poor response to chemotherapy, with resistance and recurrent disease being prevalent. siRNA technology is currently being explored in clinical trials as a form of targeted therapeutic strategy in the disease. RBBP6 is a 250kD protein that enhances MDM2-mediated ubiquitination of p53 and also plays a role in cell cycle regulation and cell differentiation. It is upregulated in numerous cancers such as lung, oesophageal, colorectal and cervical cancer. RBBP6 suppresses p53 binding to DNA thereby inhibiting p53-dependent gene transcription. RBBP6 was knocked down using 30 nM siRNA in RMG-1 cells for 48 hours, after which the cells were treated with 50 nM paclitaxel and 0.5μM camptothecin for 24 hours. xCELLigence real time cell analysis was used to evaluate cell proliferation. qPCR and western blot were used to evaluate both gene expression and protein expressions respectively, of Bax, Bcl-2, MDM2, p53 and p21. Flow cytometry was used to determine the mode of cell death elicited apoptosis and also analyse changes in cell cycle progression. qPCR and Western blot analyses showed that RBBP6 expression reduced by approximately 57%. There was a significant upregulation of p53 and a significant downregulation of Bcl-2 in siRBBP6 transfected cells (p<0.05). Knockdown of RBBP6 resulted in a 37±5.8% cell death. There was a significant increase in cell death in paclitaxel and siRBBP6 co-treated cells (81.6±0.79%) as compared to cells treated with paclitaxel only (76.±1.14%). siRNA-mediated knock down of RBBP6 induces cell death in RMG-1 ovarian carcinoma cells. In addition, paclitaxel-induced cell death in RMG-1 cells is potentiated by RBBP6 siRNA transfection. A combination of chemotherapy with paclitaxel or camptothecin and RBBP6 siRNA could be a possible therapeutic strategy in combatting ovarian carcinomas.Item HIV-1 subtype B and C GP120-mediated apoptosis of bystander CD4+ T lymphocytes(2012-03-06) Pillay, Natasha CamillaHuman Immunodeficiency Virus type 1 (HIV-1) is the causal agent of AIDS, and currently infects 33.3 million individuals worldwide. The gradual depletion of CD4+ T lymphocytes is a characteristic feature of a progressive HIV-1 infection. During HIV-1 infection the number of infected CD4+ T lymphocytes is fewer than the number of CD4+ T lymphocytes that are depleted, therefore suggesting a role for HIV-mediated apoptosis of uninfected bystander CD4+ T lymphocytes. Apoptosis, also known as programmed cell death, is a highly regulated, normal physiological process that results in the disposal of unwanted or corrupted cells such as virally infected cells. Several HIV-1 proteins are involved in HIV-1-mediated apoptosis, of which the envelope (Env) glycoprotein gp120 subunit is the most effective. However, the true mechanism of gp120-mediated apoptosis of uninfected CD4+ T lymphocytes is not fully understood and remains controversial. Furthermore, research focusing on HIV-1 subtype C Env-mediated apoptosis is limited. This study compared the ability of CCR5-utilizing soluble monomeric HIV-1 subtype C gp120 (gp120ZM651), monomeric HIV-1 subtype B gp120 (gp120BaL) and trimeric/oligomeric HIV-1 subtype C gp140 (gp140AncC) to induce apoptosis of uninfected Jurkat T lymphocytes and activated CD4+ T lymphocytes via CD4 and CD4/CCR5 signalling, respectively. All three Env glycoproteins were expressed in HEK 293T cells, purified by lectin affinity chromatography and characterized by assessing their binding capabilities to monoclonal antibodies IgGb12, 17b (in the presence and absence of soluble CD4) and 2G12. Purified recombinant gp120BaL, gp120ZM651 and gp140AncC were found to v be functional and conformationally intact and subsequently added in different concentrations to uninfected Jurkat T lymphocytes and activated CD4+ T lymphocytes. Apoptosis was detected by flow cytometry using Annexin V/7-AAD staining for up to 48 hours post treatment, and further confirmed by TUNEL analysis at 65 hours post treatment. Recombinant gp120BaL, gp120ZM651 and gp140AncC induced low levels of apoptosis in the Jurkat T lymphocytes (6.1%, 5.0% and 6.8%, respectively) and higher levels of apoptosis in the activated CD4+ T lymphocytes (13.3%, 15.6% and 11.5%, respectively) via TUNEL analysis of chromosomal DNA fragmentation. Moreover, comparable levels of apoptosis were observed between the monomeric gp120 and trimeric/oligomeric gp140 forms in both cell types. Interestingly, the subtype C gp140AncC induced higher levels of apoptosis than subtype C gp120ZM651 and subtype B gp120BaL in activated CD4+ T lymphocytes during the Annexin V/7-AAD analysis while the subtype C gp120ZM651 induced higher levels of apoptosis than subtype C gp140AncC and subtype B gp120BaL in activated CD4+ T lymphocytes during the TUNEL analysis. Overall, these results suggest that soluble gp120 is able to mediate low levels of apoptosis via CD4 signalling only in Jurkat T lymphocytes, and these levels are enhanced in activated CD4+ T lymphocytes, possibly due to engagement of gp120 with CD4 and the CCR5 co-receptor on the surface of the target cell.Item The relationship between hepatitis b virus and apoptosis in humans and in a transgenic mouse model(2012-01-17) Viana, Raquel ValongoHepatitis B virus (HBV) has been found to be highly endemic in Africa and south east Asia. In southern Africa, subgenotype A1 and genotype D prevail while in south east Asia genotype B and C predominate. Infection with HBV can lead to a wide spectrum of clinical presentations ranging from an asymptomatic carrier state to self-limited acute or fulminant hepatitis to chronic hepatitis with progression to cirrhosis and hepatocellular carcinoma (HCC). It has been shown that viral factors as well as a number of host and environmental factors can influence the course of HBV infection. Development and progression of various liver diseases are associated with either an increase or decrease in hepatocyte apoptosis. Dysregulated apoptosis itself may be a fundamental feature of most acute and chronic human liver diseases. The purpose of this study was to characterise the subgenotype A1 and genotype D HBV infection, prevailing in South Africa. To control for the influence of host factors on HBV infection as well as to avoid the use of in vitro cell lines, such as Huh-7, that have defective apoptotic pathways, the in vivo urokinase plasminogen activator severe combined immunodeficient (uPA-SCID) transgenic mouse model was utilised. The HBV infection of the transgenic mice infected with HBV positive sera containing either subgenotype A1 wildtype, subgenotype A1 with the G1862T mutation, subgenotype A2 or genotype D, was compared. For the first time, we were able to demonstrate the successful infection of the uPA-SCID transgenic mouse model with subgenotype A1 of HBV. The successful establishment of the in vivo HBV infection with different genotypes or subgenotypes in the uPA-SCID transgenic mice was demonstrated by the increase of HBV DNA levels, the presence of cccDNA and HBV transcripts as well as the detection of the core and/or surface HBV antigens in the liver tissue of the chimeric mice. Differences between the HBV infections with the various genotype/subgenotypes were observed. Subgenotype A1 with the G1862T mutation showed the earliest detection and therefore highest levels of cccDNA as well as the highest HBV DNA levels when compared to the other strains. The highest HBV DNA levels were recorded for the subgenotype A1 G1862T infected transgenic mouse followed by genotype D, subgenotype A2 and the lowest levels observed in the subgenotype A1 wild-type infected transgenic mouse. HBsAg was also only detected in the livers of mice infected with subgenotype A1 with the G1862T mutation. HBcAg staining in the chimeric liver was positive when the mice were infected with genotype D, which concurs with previous observations that genotype D is characterised by high HBcAg expression. Subgenotype A1 with the 1862 mutant showed the highest levels of apoptosis as a result of the abnormal precore precursor protein accumulation shown to be associated with this 1862 missense mutation. Thus different genotypes and subgenotypes as well as variations within genotypes can influence HBV infection. Moreover, the results of these experiments in the immunocompromised chimeric mice, grafted with liver cells from a single donor, suggests that even when host and environmental risk factors are controlled for, the subgenotype or genotype can influence the course of infection. The limitations of the uPA-SCID transgenic mouse model include the lack of an immune system and the short life-span of the animal; therefore a population based study was carried out to investigate the influence of host factors on HBV infection in various disease groups. The study cohort comprised 635 serum samples from South Africa, China and Japan. Of these samples, 564 were HBsAg-positive and the remaining 71 HBsAg-negative, HBV DNA negative controls. The study cohort included asymptomatic carriers; chronically infected HBV patients as well as patients with HBV associated HCC. Possible associations were determined between HBV genotype, HBV viral load, apoptosis levels, disease group and the age and gender of the patient where available. Apoptosis levels were quantified by the measurement of cleaved cytokeratin 18 (M30) in serum. Patients infected with genotype C or subgenotype A1 were shown to possess a higher odds ratios of developing HCC compared to subgenotype B2 or genotype D, respectively. Significantly higher HBV viral loads were observed in genotype C compared to subgenotype B2. Among the Asian cohort, it was also shown that the male gender was positively associated with high viral loads in HCC patients. Moreover, a positive association between higher HBV viral load levels and HCC in the South African cohort was observed. Male gender, older age, HBV viral load, subgenotype A1 and the presence of the G1862T mutation were shown to be positively and significantly associated with higher levels of apoptosis. In this study it was discovered that the levels of cleaved cytokeratin 18 could potentially be used as a biomarker for the severity of HBV infection because a significant difference was observed with the apoptosis levels between the asymptomatic and HCC patient disease groups. We conclude that even when the influence of host and environmental factors is controlled for, as is the case in the chimeric mouse model, the HBV genotype can affect the progression of infection. Moreover, it was shown in the population based study that the effect of HBV genotype on the outcome of HBV infection can be influenced by host factors. The subgenotype A1 G1862T mutation was shown in both studies to affect both HBV infection and apoptosis. This suggests that HBV variants should be investigated to ascertain their potential impact on the course of HBV infection as it may differ from the wild-type. Apoptosis was shown to be associated with HBV infection in both studies and could possibly be an ideal marker of the progression of HBV infection. These findings are important in helping us to understand factors influencing the course of HBV infection. We have therefore shown in both the studies that differences do exist between the South African subgenotype A1 and genotype D, and that these differences should be taken into consideration for the future evaluation of HBV infection and treatment of South African HBV infected patients. Moreover, cleaved cytokeratin 18 may provide an ideal surrogate marker for HBV disease progression and monitoring.Item Molecular mechanisms of apoptosis in lung cancer: a role for retinoblastoma binding protein 6 (RBBP6) and its protein products(2010-08-24) Motadi, Lesetja RaymondRBBP6 (retinoblastoma binding protein 6) is a 250-kDa multifunctional protein that interacts with both p53 and pRb and has been implicated in mRNA processing. It has also been identified as an E3 ubiquitin ligase due to the presence of a RING finger domain and also assumed to have a regulatory role of p53 due to the presence p53BD through MdM2, although no substrate has been identified up to now. RBBP6 gene mutants are reported to be resistant to apoptosis inducers, which led to a belief that mutation of this gene might result in the development of lung cancer. Earlier localization and expression studies have shown that RBBP6 expression and apoptosis levels are indirectly proportional. The purpose of this study is to establish the expressional pattern of the RBBP6 gene in lung cancer at both mRNA and protein levels. The objective is also to characterize the role of this gene and apoptosis in diverse lung diseases. An understanding of the role of RBBP6 in the development of lung diseases may lead to insights into developing new therapeutic measures for those lung diseases in which apoptosis plays a prominent part. This thesis elucidate the possible role of RBBP6 in lung cancer and apoptosis, to establish tissue distribution and expression levels of RBBP6 at protein and mRNA levels in lung cancer by immunocytochemistry (ICC), in situ hybridization (ISH) and confirm findings by quantitative RT-PCR. RBBP6 mRNA transcripts were expressed in the cytoplasm of normal and tumour lung epithelium. In general, expression was highest in the cytoplasm of welldifferentiated carcinoma and invasive carcinoma that showed signs of cells undergoing mitosis. Immunolabelling results further showed high level of expression in all lung cancer types except in Small and large cell carcinomas. The immunolabeling were confirmed by ISH experiments and RT-PCR. In relation to p53, RBBP6 mRNA expression was higher in lung cancer cell lines that had p53 silenced and apoptosis induced by TRAIL and camptothecin. There was no notable change in the levels of p53 expression following RBBP6 silencing and apoptosis induction. However, there was a little correlation between RBBP6 expression and apoptosis levels in both lung cancer tissues by TUNEL and lung cancer cell line following apoptosis induction by TRAIL. The ratio of Bax/Bcl-2 was seen to be upregulated following p53 and RBBP6 silencing after apoptosis induction. The most common mutation notable after RBBP6 DNA sequencing was point mutations where only single nucleotide was mutated and mostly they were observed in lung cancer tissues. This was the first demonstration that RBBP6 is expressed in lung cancers. Because of the ubiquitin-like nature of the protein and its localized up-regulation and corresponding proapoptotic activity in lung cancer cells, it is possible that further characterization of this gene could lead to its manipulation as a diagnostic marker and a potential therapeutic target for cancer treatment.Item Characterization of 1-ACBP B-ACBP and PBR in oesophageal cancer(2006-10-27T07:44:47Z) McCabe, Michelle LynnBackground: Cancer of the oesophagus ranks as the ninth most common malignancy in the world, and recent evidence shows that its incidence is increasing. Apoptosis is a process of programmed cell death, which is as essential as cell growth, for the maintenance of homeostasis. When these processes lose integration, such as cancer, then uncontrolled cell growth occurs. There are at least five ACBP subgroups and the two being focused on in this study is B-ACBP (brain specific) and 1-ACBP (found in nearly all tissues). ACBPs act as intracellular carrier-proteins for medium to long chain acyl-coA, mediating fatty acid transport to the mitochondrion for ß-oxidation. ACBPs are also believed to be putative ligands of PBR (Peripheral Benzodiazepine Receptor), and bound to this receptor facilitates mitochondrial membrane permeabilization giving the notion that it favours apoptosis. Aim: To establish the expression patterns of 1-ACBP, B-ACBP, and PBR in oesophageal cancer, and to characterize their roles in this disease. Methodology: Paraffin-embedded sections of normal and malignant oesophageal tissues were utilized for localization studies. RNA probes was synthesized and labelled using Digoxigenin for colorimetric and fluorescent detection during the in situ hybridization (ISH) technique for localization. Real time quantitative RT-PCR was performed to determine the expression levels of the three genes in oesophageal cancer RNA using the Roche Lightcylcer .Results: All three genes showed substantial upregulation within the malignant tissue sections compared to normal oesophageal sections, all three transcripts localized specifically to plasma cells and lymphocytes in diseased and normal tissue section. In the diseased tissue B-ACBP and 1-ACBP mRNA localized to endothelial cells of blood vessels in the submucosa. B-ACBP also localized to the nucleus of squamous epithelium cells. PBR localization occurred in tumour islands in invasive tissue sections. Quantitative RT-PCR also illustrated PBR expression level was the highest compared to the ACBP genes expression in tumours. Conclusion: These results show that 1-ACBP, B-ACBP and PBR play a role in the pathogenesis of oesophageal cancer as well as immunology. Further experiments are still required to determine the function of these genes and the role they play in apoptosis and oesophageal cancer.